Lupin shares climbed on Thursday after the US Food and Drug Administration gave tentative approval to the company to sell a generic version of an HIV treatment. While the approval is tentative and pending patent and exclusivity clearance, analyst Varunkumar Patel said it places Lupin in a strong position to capture a high-value, stable demand market once launch is viable.